MedTrace Logo

Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults

NCT02231281 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2018-04-26

No results posted yet for this study

Summary

The purpose of this study is to assess the ability of the early initiation of cART or cART in combination with autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion to achieve a post-treatment control among treatment-naïve acute HIV-infected adults.

Conditions

  • Acute HIV Infection

Interventions

DRUG

cART(TDF/AZT+3TC+LPV/r)

Standard antiretroviral therapy for HIV infection

PROCEDURE

CTL infusion

cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion

Sponsors & Collaborators

  • Tang-Du Hospital

    collaborator OTHER

  • National Center for AIDS/STD Control and Prevention, China CDC

    collaborator OTHER_GOV

  • Beijing YouAn Hospital

    collaborator OTHER

  • China Medical University, China

    collaborator OTHER

  • Shandong Province Centers for Disease Control and Prevention

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Yongtao Sun, MD, PhD

    lead OTHER

Principal Investigators

  • Yongtao Sun, M.D., Ph.D. · Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2018-08-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02231281 on ClinicalTrials.gov